4-[[3-[4-(1-Carbamimidoylpiperidine-4-carbonyl)piperazine-1-carbonyl]-5-nitrophenyl]methyl]piperazine-1-carboximidamide | 1379573-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[[3-[4-(1-Carbamimidoylpiperidine-4-carbonyl)piperazine-1-carbonyl]-5-nitrophenyl]methyl]piperazine-1-carboximidamide
• CAS: 1379573-93-9
• 化学式: C₂₄H₃₆N₁₀O₄
• 分子量: 528.614
• InChiKey: LXRANMYCEOPTJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  196
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells
  申请人：THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BE HALF OF THE UNIVERSITY OF N

  公开号：US20160120862A1

  公开（公告）日：2016-05-05

  Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及一种赖氨酸特异性去甲基化酶I（LSD1）的抑制剂，合成该化合物的方法，包含该化合物的制药组合物以及使用该化合物和组合物治疗存在Sox2的癌症的方法。本发明还涉及使用LSD1和/或组蛋白去乙酰化酶I（HDAC1）的抑制剂治疗存在Sox2的癌症的方法。本摘要旨在作为搜索特定领域的扫描工具，不限制本发明。
• US9918983B2
  申请人：——

  公开号：US9918983B2

  公开（公告）日：2018-03-20
• [EN] NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS<br/>[FR] NOUVEAUX INHIBITEURS SUICIDES DE LA LSD1 CIBLANT LES CELLULES CANCÉREUSES EXPRIMANT LE SOX2
  申请人：UNIV NEVADA

  公开号：WO2014194280A2

  公开（公告）日：2014-12-04

  Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD 1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.